Clinical Trials Logo

Biliary Tract Cancer clinical trials

View clinical trials related to Biliary Tract Cancer.

Filter by:

NCT ID: NCT03260712 Completed - Metastatic Cancer Clinical Trials

Pembrolizumab in Biliary Tract Cancer

Start date: January 7, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm, multi-centre, phase II study in biliary tract cancer (BTC) patients. The main objective is to detect an increase in progression-free survival rate at 6 months (according to RECIST version 1.1) from 60% in patients with BTC treated with standard chemotherapy (CT) approach to 75% when treated with CT combined with pembrolizumab.

NCT ID: NCT03231176 Completed - Clinical trials for Biliary Tract Cancer

Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

Start date: December 19, 2017
Phase: Phase 2
Study type: Interventional

This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER4. Varlitinib may be beneficial to subjects with cancer by simultaneous inhibition of these receptors. The purpose of this study is to determine the safety and efficacy of Varlitinib in combination with capecitabine for the treatment of Biliary Tract Cancer. Eligible patients will receive Varlitinib plus capecitabine.

NCT ID: NCT03185988 Recruiting - Colorectal Cancer Clinical Trials

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Start date: July 1, 2017
Phase: Phase 2
Study type: Interventional

To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response rate (RR) determined by the Investigator using RECIST 1.1, and provide evidence for phase III clinical trial.

NCT ID: NCT03144856 Recruiting - Clinical trials for Biliary Tract Cancer

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Start date: February 22, 2017
Phase: Phase 2
Study type: Interventional

This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.

NCT ID: NCT03110510 Withdrawn - Clinical trials for Biliary Tract Cancer

FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Start date: September 6, 2019
Phase: Phase 2
Study type: Interventional

FOLFIRI as a salvage treatment in metastatic biliary tract cancer (BTC) patients who failed gemcitabine containing chemotherapy

NCT ID: NCT03110484 Recruiting - Clinical trials for Biliary Tract Cancer

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Start date: July 9, 2021
Phase: Phase 2
Study type: Interventional

Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabine containing chemotherapy

NCT ID: NCT03110328 Completed - Clinical trials for Biliary Tract Cancer

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Start date: February 7, 2018
Phase: Phase 2
Study type: Interventional

eligible subjects will receive treatment beginning on Day 1 of each 3-week dosing cycle for pembrolizumab. Treatment with pembrolizumab will continue until documented disease progression, unacceptable adverse event(s),intercurrent illness that prevents further administration of treatment, Investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, subject receives 24 months of pembrolizumab, or administrative reasons requiring cessation of treatment.

NCT ID: NCT03093870 Completed - Clinical trials for Biliary Tract Cancer

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

TreeTopp
Start date: July 4, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER4. Varlitinib may be beneficial to subjects with cancer by simultaneous inhibition of these receptors. The purpose of this study is to determine the safety and efficacy of Varlitinib in combination with capecitabine for the treatment of Biliary Tract Cancer. Treatment groups are Varlitinib+capecitabine and Placebo + capecitabine

NCT ID: NCT03079427 Completed - Cholangiocarcinoma Clinical Trials

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

Start date: May 15, 2017
Phase: Phase 2
Study type: Interventional

There is no proven adjuvant treatment after curative surgical resection in patients with cholangiocarcinoma, although previous meta-analysis suggested potential survival benefit of adjuvant chemotherapy or radiotherapy in patients with lymph node-positive resected cholangiocarcinoma. Despite of lack of level 1 evidence and no data which regimen is optimal, adjuvant chemotherapy is widely used in daily practice setting. Based on this background, the investigators designed the randomized phase 2 trial comparing capecitabine and gemcitabine plus cisplatin in patients with resected lymph node-positive extrahepatic cholangiocarcinoma.

NCT ID: NCT03044587 Active, not recruiting - Clinical trials for Biliary Tract Cancer

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

NIFE
Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial